Background {#Sec1}
==========

Liver cancer is a common malignancy, and its mortality rate ranks third among malignant tumors; hence, this disease represents a serious threat to health and life \[[@CR1]\]. Cirrhosis, caused by persistent hepatitis C virus (HCV) infection, is a key factor in the development of hepatocellular carcinoma (HCC) \[[@CR2]--[@CR4]\], while chronic hepatitis B virus (HBV) carriers are 100 times more likely to develop HCC than non-carriers \[[@CR5]--[@CR7]\]. HCV infection is a common cause of HCC in western countries and Japan, while HBV frequently causes HCC in other parts of Asia and developing countries \[[@CR8]\].

Major histocompatibility complex class I-related gene A (*MICA*) is a tumor-associated gene containing numerous polymorphisms, which maps to the short arm of human chromosome 6 \[[@CR9]\]. MICA is highly expressed in tumor cell lines and epithelial-derived primary tumors, such as lung, breast, liver, and prostate cancers \[[@CR10]\]. MICA protein is a ligand of the NK cell surface activating receptor, NKG2D, which can effectively mediate NK cell killing of tumor cells by binding activation proteins \[[@CR11]\]; however, many MICA-positive tumors release soluble MICA (sMICA) into the serum, which inhibits NK cell function \[[@CR12]\]. *MICA* polymorphisms are associated with the development of numerous diseases, including cancer and autoimmune diseases \[[@CR13], [@CR14]\].

The rs2596542 single nucleotide polymorphism (SNP) in the *MICA* promoter region may be associated with HCC induced by HCV \[[@CR15]\], while the results of studies investigating the association of rs2569542 with susceptibility to HBV/HCV-induced HCC are variable \[[@CR16]--[@CR18]\], limiting their credibility. The aim of this study was to perform a meta-analysis of published reports concerning rs2596542 and HCC susceptibility, to provide more reliable evidence for basic research and clinical treatment.

Methods {#Sec2}
=======

Search strategy {#Sec3}
---------------

A comprehensive search of three databases (MEDLINE, Web of Science, and Embase) was performed and relevant publications were retrieved by literature traceability, from inception to April 2019. The search phrase used was: ("liver cell carcinoma" or "carcinoma, hepatocellular" or "Hepatocellular carcinoma" or HCC or hepatoma) AND (MICA or "MHC class I polypeptide-related sequence A" or "Human Major Histocompatibility Complex class I polypeptide-related sequence A") AND ("polymorphism" or "SNP" or "variation" or "variants" or "locus" or "mutation").

Literature selection {#Sec4}
--------------------

All retrieved publications were screened by stepwise assessment of the title, abstract, and full text, according to the preset inclusion and exclusion criteria described below. Two independent investigators (Luo and Wang) conducted this work simultaneously, and any disagreement was resolved by discussion with a third investigator.

Inclusion criteria: (1) Studies including rs2596542 genotype and allele frequency data from patients with virus-induced live cirrhosis (LC), chronic hepatitis C (CHC)/chronic hepatitis B (CHB), and HCC; (2) Case-control studies; (3) Sufficient data to calculate an odds ratio (OR) and corresponding 95% confidence interval (CI); (4) In repeatedly published studies, the report with higher quality data and more comprehensive outcomes data, was selected; (5) English language.

Exclusion criteria: (1) Letters, notes of meetings, reviews, etc.; (2) Data could not be extracted.

Quality assessment of the studies and data extraction {#Sec5}
-----------------------------------------------------

Quality assessment of the studies and data extraction were performed independently by two investigators (Shen and Deng), based on a set of predetermined criteria (Table [1](#Tab1){ref-type="table"}) extracted and modified from previous studies \[[@CR19]--[@CR23]\]. Any disagreement was resolved by discussion with a third investigator. Quality scores ranged from 0 to 10, with higher scores representing better quality. The following information was extracted: first author, year of publication, country, the characteristics of participants in each study, sample size, number of cases, number of controls, sample source, detection method, and Hardy-Weinberg equilibrium (HWE) in controls. Table 1Scale for methodological quality assessmentCriteriaScore1.Representativeness of cases 1.1 HCC and LC diagnosed according to acknowledged criteria.2 1.2 Mentioned the diagnosed criteria but not specifically described.1 1.3 Not Mentioned.02.Source of controls 2.1 Cases and control from the same cohort1  2.1.1 Defined HCC-free controls according to clinical, biochemical and serological parameters2  2.1.2 Only defined HCC-free controls as CHB or LC but not described1 2.2 Not described03.Sample size 3.1 \> 3002 3.2100--3001 3.3 \< 10004.Quality control of genotyping methods 4.1 Repetition of partial/total tested samples with a different method2 4.2 Repetition of partial/total tested samples with the same method1 4.3 Not described05.Hardy-Weinberg equilibrium (HWE) 5.1 Hardy-Weinberg equilibrium in control subjects1 5.2 Hardy-Weinberg disequilibrium in control subjects0

Statistical analysis {#Sec6}
--------------------

The chi-square test was used to assess HWE in control populations, with *P* \> 0.05 considered to indicate consistency with HWE. Meta-analysis was performed using SAS 9.2 (SAS Institute Inc., Cary, NC, USA) and STATA 12.0 (STATA Corp, College Station, TX, USA) software. Pooled OR and 95% CI values were calculated to evaluate the association of *MICA* rs2596542 with susceptibility to HBV/HCV-induced HCC, based on five genetic models: 1) allelic, C vs. T; 2) heterozygous, CT vs. CC; 3) homozygote, TT vs. CC; 4) dominant, TT/CT vs. CC; and 5) recessive, TT vs. CC/CT. When heterogeneity existed among different studies (*P* value of Q test \< 0.10 and/or I^2^ \> 50%), pooled OR values were calculated using a random effect model, while a fixed effect model was used when heterogeneity analysis indicated *P* \> 0.10 and/or I^2^ \< 50%. Publication bias was checked using Egger's test, and Begg's linear regression with funnel plots, and was considered present when *P* \< 0.05, or the funnel plot was asymmetrical \[[@CR24]\].

Results {#Sec7}
=======

Study identification and selection {#Sec8}
----------------------------------

A total of 148 documents were retrieved from PubMed (*n* = 36), Embase (*n* = 61), and Web of Science (*n* = 51) databases, of which 70 were eliminated, due to duplicate publication. The remaining 78 articles were initially screened, based on the title and abstract, and 59 articles excluded for other reasons, including that: they were reviews, abstract compilations, or meeting reports (*n* = 30); they investigated other genes (*n* = 4); they only reported the relationship between sMICA expression and HCC (*n* = 9); or they investigated other diseases (*n* = 15). Finally, the full text documents of the remaining 20 articles were read, following which, nine were eliminated because they contained unsuitable data, such as corrigendum (*n* = 1), no extractable data (*n* = 4), no controls (*n* = 2), duplicate data (n = 1), and unclear virus infection (*n* = 1). Finally, 11 eligible publications \[[@CR15]--[@CR18], [@CR25]--[@CR31]\] were included in the meta-analysis (Fig. [1](#Fig1){ref-type="fig"}). Fig. 1Flow diagram of the literature search and selection process

General characteristics of the included studies {#Sec9}
-----------------------------------------------

The 11 articles included in the study involved 25,677 blood samples from 4582 patients with HCC and 21,095 non-HCC patients. The subjects included Chinese, Japanese, Egyptian, Swiss, Vietnamese, and Italian individuals infected with HCV or HBV. Quality scores were \> 6, indicating that this meta-analysis included high quality studies. SNP data from the control groups of the 11 studies were consistent with HWE. The general characteristics of the included studies are presented in Table [2](#Tab2){ref-type="table"}. Table 2General characteristics description of the included studiesStudy (first author/year)CountryEnrolled populationAnti-HCVAnti-HBVAnti-HIVCaseNo-HCCNo.(HCC/no-HCC)Sample sourceMethodHWEScoreAmal A. Mohamed/2017EgyptHCV-infected patientspositivenegativenegativeHCCLC, healthy47/94blood samplesTaqMan ViiA 7 Real Time PCR SystemYes6Chung-Feng Huang/2017ChinaHCV-infected patientspositivenegativenegativeHCCLC, HCV patients58/647blood samplesABI TaqMan® SNP genotyping assaysYes7H. V. Tong/2013VietnamHBV-infected patientsnegativepositivenegativeHCCLC, CHB, ASYM, non-HBV healthy163/776blood samplesasymmetrical PCRYes9Hoang Hai/2017JapanHCV-infected patientspositive----HCCno-HCC257/1098blood samplesTaqMan SNP Genotyping Assays and direct sequencingYes8Kangmei Chen/2013ChinaHBV-infected patientsnegativepositivenegativeHCCCHB506/772blood samplesTaqMan assays and 5% samples were randomly selected and directly sequencedYes9Maria Antonella Burza/2016ItalyHCV-infected patientspositivenegativenegativeHCCLC, no/mild fibrosis142/311blood samplesTaqMan assaysYes8Paulisally Hau Yi Lo /2013JapanHCV-infected patientspositivenegativenegativeHCCLC, CHC1394/1629blood samplesIllumina HumanHap610-Quad BeadChip or invader assayYes9Vinod Kumar/2011JapanHCV-infected patientspositivenegativenegativeHCCnon-HCV control1394/7217blood samplesmultiplex PCR-based Invader assay and the Illumina HumanHap610-QuadYes9Vinod Kumar/2012JapanHBV-infected patientsnegativepositivenegativeHCCCHB, non-HBV control407/6356blood samplesIllumina Human Hap610-Quad and Human Hap550v3/Invader assay systemYes9Giuseppa Augello/2018ItalyHCV-infected patientspositivenegativenegativeHCCLC healthy150/335blood samplesCompetitive Allele-Specific KASP™ SNP genotyping platformYes8Christian M. Lange/2013SwitzerlandHCV-infected patientspositivenegativenegativeHCCCHC64/1860blood samplesfluorescent-based competitive allele-specific PCR genotyping systemYes7

Meta-analysis {#Sec10}
-------------

Our analyses demonstrated heterogeneity among the results generated using the five genetic models \[I^2^ \> 50%, *P* (heterogeneity) \< 0.10\] (Table [3](#Tab3){ref-type="table"}). Therefore, the results were pooled under a random effects model, and the results of the analysis showed that, under the recessive model, rs2569542 TT was a risk factor for the development of HBV/HCV-induced HCC. Individuals carrying the TT genotype were more genetically susceptible to HCC compared with other individuals \[TT vs. CC/CT: OR = 1.248 (95% CI: 1.040--1.499), *P* = 0.017\] (Table [3](#Tab3){ref-type="table"}, Fig. [2](#Fig2){ref-type="fig"}). Table 3Combined results of genotype frequencies in HCC and non-HCC groups in different genetic modelsExposureNo-exposureOR(95% CI)*P* (OR)I-squared*P* (Heterogeneity)*P* (Begg's test)*P* (Egger's test)TC1.102 (0.974, 1.248)0.12477.2%0.0000.5330.156CTCC1.041 (0.882, 1.230)0.63470.3%0.0000.8760.247TTCC1.279 (1.000, 1636)0.05072.7%0.0000.4360.191TTCT/CC1.248 (1.040, 1.499)0.01760.3%0.0050.3500.194TT/CTCC1.086 (0.911, 1.295)0.35676.7%0.0000.6400.253 Fig. 2Forest plots of rs2596542 and HCC in different genetic models

Subgroup analyses {#Sec11}
-----------------

Subgroup analyses were conducted under the recessive model, according to control type, virus infection, and ethnicity. Patients with the TT genotype had higher susceptibility to HCC, regardless of whether they were HCV-infected (OR = 1.326, 95% CI: 1.101--1.599, *P* = 0.003), Asian (OR = 1.273, 95% CI: 1.002--1.618, *P* = 0.048), or were compared to a CHC control population (OR = 1.506, 95% CI: 1.172--1.936, *P* = 0.001) (Table [4](#Tab4){ref-type="table"}, Additional file [1](#MOESM1){ref-type="media"}: Figure S1). Table 4Subgroup analysis results under recessive modelGroupSubgroupNo. of studyHBV/HCV patientOR(95% CI)*P* (OR)I-squared*P* (Heterogeneity)ControlsLC54891.216 (0.984, 1.502)0.0700.0%0.457CHC411791.506 (1.172, 1.936)0.00158.2%0.067CHB32431.218 (0.743. 1.997)0.43466.1%0.052Healthy516591.255 (0.899, 1.750)0.18268.6%0.013Population-basedHCV-infected patients824521.326 (1.101, 1.599)0.00349.1%0.056HBV-infected patients39361.133 (0.718, 1.788)0.59172.5%0.026EthnicityAsian731351.273 (1.002, 1.618)0.04874.0%0.001European336131.065 (0.787, 1.440)0.6840.0%0.455

Publication bias {#Sec12}
----------------

Publication bias was analyzed under the different genetic models, using Begg's test to plot funnel diagrams. Ten studies among the 11 included articles are presented in the plots, and their data points were scattered and distributed, with the pooled OR value at the center; that is, they basically formed a symmetrical, inverted funnel-shape (Fig. [3](#Fig3){ref-type="fig"}). Analysis using Egger's test demonstrated that all *P* values were \> 0.05, suggesting no publication bias (Table [3](#Tab3){ref-type="table"}). Fig. 3Funnel plots of Begg's test to evaluate publication bias in the included studies

Discussion {#Sec13}
==========

This study systematically evaluated the relationship between rs2596542, in the *MICA* gene promoter, and HCC susceptibility. The results suggest that HBV/HCV-infected individuals carrying the TT genotype at this locus are more likely to develop HCC than those carrying other genotypes, particularly if they are HCV-infected or of Asian ethnicity. This may be due to the persistent HBV/HCV infection associated with the TT genotype \[[@CR27], [@CR31]\]. Further, infection with HBV/HCV can cause up-regulation of matrix metalloproteins, high levels of which lead to increased production of sMICA and decreased membrane-bound MICA tumor antigen protein \[[@CR32], [@CR33]\]. These changes ultimately inhibit the anti-tumor effects of immune cells and facilitate the immune escape of HCC cells \[[@CR10], [@CR12]\].

Compared with two previously published articles \[[@CR24], [@CR34]\], this study explores the relationship between rs2596542 and susceptibility to HBV/HCV-induced HCC. Only studies including cases of HBV/HCV-induced HCC were included in this meta-analysis, which used differing raw data and generated different results from previous studies. Among patients with persistent HCV infection, those with the TT genotype at rs2569542 are more likely to develop HCC, which is consistent with results of studies in Asian populations, suggesting that the susceptibility of HBV/HCV-induced HCC is not only related to individual genetic factors, but also to viral infection and geographical region. Heterogeneity remained after subgroup analysis, which may be because we did not consider the effect of viral genotype, sex, or complications on the influence of genotype on HCC risk.

In this study, a qualitative Begg's test plot and quantitative Egger's test analysis showed no significant publication bias, indicating that the combined results are reliable; however, the study had some limitations. First, the publications included in this study were limited to texts published in English, hence publication and cultural bias may still have affected the results of the meta-analysis. Second, the majority of genotype data in this study were derived from Chinese and Japanese individuals; this lack of genotype data from other ethnic groups reduces the wider applicability of our findings.

Conclusion {#Sec14}
==========

In summary, rs2596542 is a molecular marker for HCC, and HCV/HBV-infected individuals carrying the TT genotype of this SNP have higher genetic susceptibility to HCC than HCV/HBV-infected individuals carrying the CT/CC genotypes. In particular, among HCV-infected populations and Asians, individuals carrying the TT genotype are more likely to develop HCC than those carrying CC/CT genotypes. This study provides a theoretical basis for the personalized treatment of virus-infected individuals with HCC.

Additional file
===============

 {#Sec15}

Additional file 1:**Figure S1.** Forest plots of rs2596542 and HCC for subgroup analyses. (JPG 1689 kb)
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